Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/79098
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Smoking termination opportunity for in patients (STOP): Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: A 12-month randomised controlled trial for inpatients |
Author: | Smith, B. Carson, K. Brinn, M. Labiszewski, N. Peters, M. Fitridge, R. Koblar, S. Jannes, J. Veale, A. Goldsworthy, S. Litt, J. Edwards, D. Esterman, A. |
Citation: | Thorax, 2013; 68(5):485-486 |
Publisher: | British Med Journal Publ Group |
Issue Date: | 2013 |
ISSN: | 0040-6376 1468-3296 |
Statement of Responsibility: | Brian James Smith, Kristin Veronica Carson, Malcolm Philip Brinn, Nadina Ann Labiszewski, Matthew J Peters, Robert Fitridge, Simon A Koblar, Jim Jannes, Antony J Veale, Sharon J Goldsworthy, John Litt, David Edwards, Adrian Jeffrey Esterman |
Abstract: | RATIONALE Smoking cessation interventions in outpatient settings have been demonstrated to be cost effective. Given this evidence, we aimed to evaluate the effectiveness of varenicline tartrate plus Quitline-counselling compared with Quitline-counselling alone when initiated in the inpatient setting. METHODS Adult patients (18–75 years) admitted with a smoking-related illness to three hospitals, were randomised to receive either 12-weeks of varenicline tartrate plus Quitline-counselling, (n=196) or Quitline-counselling alone, (n=196), with 12-months follow-up. RESULTS For the primary analysis population (intention-to-treat), the proportion of subjects who remained continuously abstinent were significantly greater in the varenicline plus counselling arm (31.1%, n=61) compared with counselling alone (21.4%, n=42; RR 1.45, 95% CI 1.03 to 2.03, p=0.03). CONCLUSIONS The combined use of varenicline plus counselling when initiated in the inpatient setting has produced a sustained smoking cessation benefit at 12-months follow-up, indicating a successful opportunistic treatment for smokers admitted with smoking related illnesses. TRIAL REGISTRATION http://www.clinicaltrials.gov/ ClinicalTrials.gov identification number: NCT01141855. |
Keywords: | Humans Benzazepines Quinoxalines Nicotinic Agonists Treatment Outcome Incidence Follow-Up Studies Smoking Smoking Cessation Counseling Time Factors Adolescent Adult Aged Middle Aged Inpatients Australia Female Male Young Adult Varenicline |
Rights: | Coopyright status unknown |
DOI: | 10.1136/thoraxjnl-2012-202484 |
Published version: | http://dx.doi.org/10.1136/thoraxjnl-2012-202484 |
Appears in Collections: | Aurora harvest 4 Surgery publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.